Titlebook: Endocrine FGFs and Klothos; Makoto Kuro-o Book 2012 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer S

FERN

書目名稱Endocrine FGFs and Klothos影響因子(影響力)




書目名稱Endocrine FGFs and Klothos影響因子(影響力)學(xué)科排名




書目名稱Endocrine FGFs and Klothos網(wǎng)絡(luò)公開度




書目名稱Endocrine FGFs and Klothos網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Endocrine FGFs and Klothos被引頻次




書目名稱Endocrine FGFs and Klothos被引頻次學(xué)科排名




書目名稱Endocrine FGFs and Klothos年度引用




書目名稱Endocrine FGFs and Klothos年度引用學(xué)科排名




書目名稱Endocrine FGFs and Klothos讀者反饋




書目名稱Endocrine FGFs and Klothos讀者反饋學(xué)科排名

Generic-Drug

Wertgenerierende Faktoren im Bankensektor,ity of endocrine FGFs. Recent structural and biochemical studies have begun to shed light onto the molecular basis for the klotho-dependent endocrine mode of action of the FGF19 subfamily. Crystal structures of FGF19 and FGF23 show that the topology of the HS binding site (HBS) of FGF19 subfamily me

痛苦一下

Arbitrary

遠地點

René K?nig und die "K?lner Schule"tients might benefit most from aggressive management of disordered phosphorus metabolism. It is also possible that markedly increased FGF23 levels in CKD could contribute directly to tissue injury in the heart, vessels and kidneys, an exciting question that is sure to be the topic of intense investi

殘暴

D. I. Hamilton,H. J. C. M. van de Waly from renal insults, preserve kidney function, and suppress renal fibrosis, in chronic kidney disease. Klotho is a highly promising candidate on the horizon as an early biomarker, and as a novel therapeutic agent for chronic kidney disease.

殘暴

Amy L. Ladd MD,Kristen Fleager MDpplied to the disease caused by loss of function of FGF23. Although these concepts still need to be proven with more detailed analyses, the latest knowledge on the FGF23-related diseases and the development of methods to appropriately regulate FGF23 actions may synergistically create novel therapeut

Spartan

Complications of Transurethral Surgery,Rs, its physiological activities, and its differences from FGF21. The review also discusses strategies to separate the mitogenic and metabolic activities for the development of potential therapeutic molecules based on FGF19.

Binge-Drinking

BRAND

FGF23 and Syndromes of Abnormal Renal Phosphate Handling,y, loss-of-function mutations in these genes underlie hypophosphatemic disorders that are either X-linked or autosomal recessive. Impaired O-glycosylation of FGF23 due to the lack of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 3 (GALNT3) or due to certain homozy